Baxter International Inc (BAX)
NYSE:BAX
Want to see BAX full AI Analyst Report?
BAX Stock Chart & Stats
$18.71
$0.05(0.17%)
At close: 4:00 PM EST
$18.71
$0.05(0.17%)
Day’s Range― - ―
52-Week Range$15.73 - $31.76
Previous CloseN/A
Volume899.70K
Average Volume (3M)6.69M
Market Cap
$10.77B
Enterprise Value$17.37B
Total Cash (Recent Filing)$2.02B
Total Debt (Recent Filing)$9.69B
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Jul 23, 2026EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend Yield2.75%
Share Statistics
EPS (TTM)-2.10
Shares Outstanding516,469,000
10 Day Avg. Volume7,034,170
30 Day Avg. Volume6,693,728
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)1.60
Price to Sales (P/S)0.87
P/FCF Ratio30.35
Enterprise Value/Market Cap1.61
Enterprise Value/Revenue1.53
Enterprise Value/Gross Profit5.10
Enterprise Value/Ebitda23.54
Forecast
1Y Price Target
$20.86Price Target Upside11.48% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)1.92
Revenue Forecast (FY)$11.36B
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained positive operating and free cash flow provide durable funding for operations, capex and debt reduction even while earnings remain weak. Strong FCF growth improves liquidity, supports the company’s stated priority of deleveraging, and preserves optionality for targeted M&A or reinvestment.
Product Launches And InnovationRegular new product introductions and digital/AI integration expand the installed base and create durable pull-through for consumables and services. New devices broaden addressable markets and strengthen competitive positioning in hospital workflows, supporting recurring revenue over multiple years.
Operational ImprovementA structured continuous-improvement program and demonstrable backorder clearance boost manufacturing reliability and throughput. Sustained productivity gains reduce cost per unit, ease supply constraints, and sustainably support margin recovery and customer service levels over the medium term.
Bears Say
Profitability PressurePersistent negative operating results and compressed gross margins limit internal reinvestment and returns generation. Until the company consistently translates revenue growth into positive operating earnings, capital allocation choices will remain constrained and recovery depends on structural margin fixes.
Meaningful LeverageElevated leverage reduces financial flexibility and increases sensitivity to interest costs and EBITDA volatility. Management’s priority to reduce net leverage is necessary; however, until leverage falls meaningfully, higher interest expense and constrained capital deployment will persist as structural headwinds.
Supply And Product RiskField actions, contract-manufacturer disruptions and sizable tariff impacts directly harm revenue and margins and can damage customer relationships. These operational and regulatory supply risks can persist into 2027, undermining consistent sales and making margin recovery harder to sustain.
Baxter International News
BAX FAQ
What was Baxter International Inc’s price range in the past 12 months?
Baxter International Inc lowest stock price was $15.73 and its highest was $31.75 in the past 12 months.
What is Baxter International Inc’s market cap?
Baxter International Inc’s market cap is $10.77B.
When is Baxter International Inc’s upcoming earnings report date?
Baxter International Inc’s upcoming earnings report date is Jul 23, 2026 which is in 36 days.
How were Baxter International Inc’s earnings last quarter?
Baxter International Inc released its earnings results on Apr 30, 2026. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.311 by $0.059.
Is Baxter International Inc overvalued?
According to Wall Street analysts Baxter International Inc’s price is currently Undervalued.
Does Baxter International Inc pay dividends?
Baxter International Inc pays a Quarterly dividend of $0.01 which represents an annual dividend yield of 2.75%. See more information on Baxter International Inc dividends here
What is Baxter International Inc’s EPS estimate?
Baxter International Inc’s EPS estimate is 0.37.
How many shares outstanding does Baxter International Inc have?
Baxter International Inc has 516,469,000 shares outstanding.
What happened to Baxter International Inc’s price movement after its last earnings report?
Baxter International Inc reported an EPS of $0.37 in its last earnings report, beating expectations of $0.311. Following the earnings report the stock price went up 4.02%.
Which hedge fund is a major shareholder of Baxter International Inc?
Currently, no hedge funds are holding shares in BAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Baxter International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.86 (11.48% Upside)
$20.86 (11.48% Upside)
Blogger Sentiment
Bullish
BAX Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.45%
12-Months-Change
Fundamentals
Return on Equity
-16.43%
Trailing 12-Months
Asset Growth
-6.84%
Trailing 12-Months
Company Description
Baxter International Inc
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
BAX Company Deck
BAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced notable operational progress (product launches, improved cash flow, continuous improvement adoption and backorder remediation) and a reiterated full-year framework against meaningful near-term financial headwinds (35% EPS decline, margin compression, Novum shipment hold and supply constraints in injectables). Management emphasized a clear turnaround plan, debt reduction priority and expected second-half recovery, but the first-half results and ongoing risks temper optimism.View all BAX earnings summariesBAX Net sales Breakdown
47.13% Medical Products and Therapies
27.31% Healthcare Systems and Technologies
22.17% Pharmaceuticals
3.39% Other
BAX Stock 12 Month Forecast
Average Price Target
$20.86
▲(11.48% Upside)
Technical Analysis
Ownership Overview
0.38% Insiders
34.64% Mutual Funds
38.39% Other Institutional Investors
0.54% Public Companies and
Individual Investors